Neoleukin therapeutics, inc. (AQXP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-75,876

-69,442

-66,228

-22,089

-19,170

-31,585

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-38,607

-

-31,421

-28,310

-22,159

-21,860

-24,287

-25,536

-26,211

-24,027

0

0

0

Non-cash items:
Change in fair value of derivative liability (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

81

99

15

5

-52

-79

26

28

949

0

0

0

Stock-based compensation (Note 5(d))

7,288

7,683

7,854

3,739

4,464

4,698

4,832

4,979

4,520

3,839

3,429

2,736

2,164

1,966

1,766

1,700

1,673

1,506

1,414

1,222

982

854

0

0

0

Stock-based purchase of patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Unrealized foreign exchange loss and others

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-197

-203

-143

-580

0

0

0

-

-

-

-

Depreciation and amortization

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Amortization of operating lease right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign exchange (gain) loss

-237

-263

-100

-285

-332

-452

-496

-400

-335

-349

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

320

0

0

0

Fees and penalty on bank loan repayment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

0

0

0

Amortization and extinguishment of remaining discount on preferred stock upon conversion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,884

0

0

0

Foreign exchange loss and others

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Receivable, prepayments and deposits

-959

-290

132

-969

-1,417

-1,041

-259

595

1,258

905

196

-178

70

109

135

422

163

96

0

0

0

-

-

-

-

Accounts and other amounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepayments and deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts payable and other liabilities

-379

-2,244

-10,132

-12,588

-6,138

-6,472

3,612

5,119

3,506

1,822

-728

137

610

4,815

4,505

4,487

671

-450

0

0

0

-

-

-

-

Net cash used in operating activities

-19,078

-15,394

-20,533

-29,395

-18,744

-31,577

-33,407

-29,543

-49,027

-44,718

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25,187

-22,357

-19,840

-20,268

-23,004

-22,575

-19,983

-17,486

0

0

0

Investing activities
Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

106,442

0

0

0

-

-

-

-

-

-

0

-

Proceeds from maturity of investments

-

-

-

-

-

56,000

0

0

0

-

-

-

-

59,097

48,631

32,677

22,155

13,196

20,877

0

0

-

-

0

-

Purchase of property and equipment

0

-

-

-

-

49

65

111

426

494

575

845

794

713

626

340

47

26

44

51

116

114

0

0

0

Net cash used in investing activities

0

-

-

-

-

55,951

72,435

100,894

94,079

64,011

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-69,034

-62,923

-51,597

-47,533

24,198

20,344

-17,509

-23,573

0

0

0

Financing activities
Public offering of common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Public offering costs (Note 8(e))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,251

0

0

0

Bank loan repayment, fees and penalty

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from exercise of stock options

0

-

-

-

-

602

0

0

0

-

-

-

-

-

-

-

-

1,120

0

0

0

-

-

-

-

Payment on finance lease obligations

9

9

9

28

30

32

34

16

15

15

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

85,629

82,237

31

-28

369

570

626

647

626

423

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

0

10

-17

-27

-57

-48

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash during the period

65,756

66,165

-20,425

-26,430

7,559

24,896

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

92,948

93,096

-29

-368

45,279

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-87

-

-54

-97

-31

-527

0

0

0

-

-

-

-

Net change in cash and cash equivalents during the period

-

-

-

-

-

-

-

-

-

-

-

-

-14,775

-

-23,148

7,554

21,408

24,620

93,504

-2,979

-38,635

3,900

0

0

0

Supplemental disclosure of cash flow information:
Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32

0

0

0

Interest received

1,536

1,544

1,753

1,828

1,831

1,684

1,556

1,455

1,309

1,342

1,210

1,069

903

695

770

547

431

325

47

68

103

91

0

0

0

Non-cash investing and financing activities:
Accrued purchase of property & equipment

-

-

-

-

-

-

-

-

-

-77

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0